Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I am trying to point out that enormous resource that is and has been directed at the Target Antigen and to find it
cancer can evade that by Loss of expression .... of MHC 1 and MHC 2
or indeed have no expression at all .............. A cold cancer
Avidmab does not need MHC 1 or MHC 11 because its locking on to specific sugars so it bypasses one area that cancer uses to evade
"""" recognise glycan-containing glycoproteins and glycolipids on the cell surface of cancer cells."""
Immunobody is bringing in High Avidity T cells that can lock onto poor MHC 1 expression ... and kill the cell.. but a poor vaccine or natural response ( high avidity is deleted in the thymus) induces T cells that are of low affinity, then the cancer can then start losing that antigen thus evading the vaccine or natural response .
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323381/
Moditope on the other hand being a CD4 with TH1 high inflammatory profile .......... forces the cancer to EXPRESS the target antigen via its MHC 11 pathway
will those same CD4 bring in other parts of the immune system to extend its full capability Ie Nk Cells ?
I asked this question to Lindy .. reply "aware of capability" but we have not looked at discovery of any "extras" principally because Moditope was so effective as a stand alone in it self. They probably did not need to look at what else is going on, as maybe they would have to build a different model to find out IMHO
and from the papers presented ... Homocitrulline induces even higher levels of cytokine forcing further expression potentially in cold cancers
That's very interesting inan.
So I take this to mean that the vast majority of focus is on mhc class I as potential targets.
But cancer is very good at suppressing the expression of mhc class I.
In contrast moditope targets class II and furthermore finds a way to increase the expression. This is what appears to make moditope unique. It finds a way to present the tumour with the unexpected. Something that apparently it finds difficult to counter.
therin lies the problem
the problem you are talking about affects the entire country ..... and how various illness can be accommodated while a pandemic is still evident
its like i said to TF 2 months ago ........ People will not wear masks correctly and struggle with the notion of social distancing
impossible to control without draconian rules and a Police Force that Polices by Fear ....
Good News thou ......... Scancell is not an Airline
Morning Inanaco, and therin lies the problem................so while the "others " ie Big Pharma are scratching heads .. what is the Target antigen ? and with the majority of cancer NOT displaying MHC 11
Scancell hits the sweet spot ..............
coming soon to a patient near you ... Modi1
It has been coming near a patient near "you" for a very long time now, it now needs to happen amogst talk of second waves and mutations, I think we can all work out why after so long we still do not have definitive timelines, hence fuelling peoples fears in many different ways.
The rise of T helper TCRs
Whereas cellular anti-tumour immune responses have typically been attributed to CD8 T cells, CD4 T cells play a critical role in tumour elimination and in the priming and maintenance of CD8 T-cell responses (recently reviewed in [33], Fig. 2). Moreover, CD4 T cells activate innate cells such as macrophages and NK cells to contribute to anti-tumour responses and can also have direct cytotoxic effect against tumour cells expressing MHC class II [34,35,36]. The use of MHC class II-restricted CD4 T cells for adoptive immunotherapy has been limited due to (1) a lack of well-characterized shared tumour antigens presented by MHC class II, (2) the majority of tumour cells being class II negative and therefore not directly presenting antigen to CD4 T cells, and (3) the lack of tools to evaluate CD4 TCR efficacy. However, the use of CD4 T cells in ACT should also circumvent one of the common tumour escape mechanisms, which is the loss of MHC class I to prevent recognition by the immune system [37]. All clinical studies of TCR therapy published to date, except one [38], have used MHC class I restricted TCRs (recently reviewed in [39]). MHC class II-restricted CD4+?T cells are able to induce more robust and broader anti-tumor immune responses which could improve outcomes in cancer immunotherapy.
Moditope forces the cells to Present MHC 11 .........................it only needs to inflame .. make hot ... create inflammation
so while the "others " ie Big Pharma are scratching heads .. what is the Target antigen ? and with the majority of cancer NOT displaying MHC 11
Scancell hits the sweet spot ..............
coming soon to a patient near you ... Modi1
https://link.springer.com/article/10.1007/s00262-019-02468-9